Publications & Posters

All categories

Publications

Posters

All Cell Engagers

AFM11

AFM13

AFM24

AFM26

All years

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

A Phase 1 Study Investigating the Combination of AFM13 and the Monoclonal Anti-PD-1 Antibody Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Data from the Dose Escalation Part of the Study

Ansell et al.
ASH 2017 – AFM13

AFM26: A first-in-class, high affinity bispecific NK-cell engager targeting BCMA to treat multiple myeloma

Gantke et al.
EACR-AACR-SIC 2017 Special Conference

High affinity bispecific EGFR/CD16A antibodies specifically recruit NK-cells to target EGFR-expressing tumors

Kluge et al.
EACR-AACR-SIC 2017 Special Conference

AFM26 is a novel, highly potent BCMA/CD16A-directed bispecific antibody for high affinity NK-cell engagement in multiple myeloma

Gantke et al.
ASCO 2017 AFM26

Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies

Ellwanger et al.
Front Oncol. 2017 May 19;7:100. doi: 10.3389/fonc.2017.00100. eCollection 2017.

link to publication

EGFR/CD16A TandAbs are efficacious NK-cell engagers with favorable biological properties which potently kill EGFR+ tumors with and without Ras mutation

Kluge et al.
AACR 2017 – AFM24

Identification of antibodies against a novel tumor-associated MHC/peptide-target and generation of highly specific and potent HLA-A*02MMP1-003/CD3 TandAbs

Weinschenk et al.
AACR 2017 – MHC

AFM26 - A novel CD16A-directed bispecific TandAb targeting BCMA for multiple myeloma

Gantke et al.
AACR 2017 – AFM26

Trispecific Antibodies for Selective CD16A-directed NK-Cell Engagement in Multiple Myeloma

Gantke et al.
ASH 2016 – Trispecific Abs

Functional Defects of NHL Patients’ T-Cells after Different Chemotherapy Regimens Activated By CD19/CD3 Tetravalent Bispecific TandAb® AFM11

Düll et al.
ASH 2016 – AFM11

1
2
3
4
5